Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Hompesch

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Diabetes Care|July 20, 2019
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to LiraglutideJulio Rosenstock, Christopher H Sorli, Michael E Trautmann, et al.
Diabetes, Obesity & Metabolism|August 18, 2017
Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjectsMichael F Crutchlow, John S Palcza, Kate M Mostoller, et al.
BMC Pharmacology & Toxicology|May 15, 2013
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitusAnita Kapur, Robin O'Connor-Semmes, Elizabeth K Hussey, et al.
Diabetes Care|October 14, 2011
Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjectsAmparo de la Peña, Matthew Riddle, Linda A Morrow, et al.
Diabetes Care|June 6, 2013
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetesRalph A DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula, et al.
Diabetes, Obesity & Metabolism|May 13, 2017
<sup>LAPS</sup> Insulin115: A novel ultra-long-acting basal insulin with a unique action profileNina Wronkowitz, Thorsten Hartmann, Sven Wolfgang Görgens, et al.
Diabetes, Obesity & Metabolism|June 24, 2017
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individualsTania Garito, Ronenn Roubenoff, Marcus Hompesch, et al.
Diabetes, Obesity & Metabolism|December 8, 2020
Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trialsCarine Beysen, Patricia Schroeder, Eric Wu, et al.
Diabetes Care|June 9, 2016
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 DiabetesAndres Digenio, Richard L Dunbar, Veronica J Alexander, et al.
Plos One|December 18, 2018
Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patientsStanko Skrtic, Björn Tyrberg, Malin Broberg, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Diabetes Care|July 20, 2019
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to LiraglutideJulio Rosenstock, Christopher H Sorli, Michael E Trautmann, et al.
Diabetes, Obesity & Metabolism|August 18, 2017
Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjectsMichael F Crutchlow, John S Palcza, Kate M Mostoller, et al.
BMC Pharmacology & Toxicology|May 15, 2013
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitusAnita Kapur, Robin O'Connor-Semmes, Elizabeth K Hussey, et al.
Diabetes Care|October 14, 2011
Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjectsAmparo de la Peña, Matthew Riddle, Linda A Morrow, et al.
Diabetes Care|June 6, 2013
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetesRalph A DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula, et al.
Diabetes, Obesity & Metabolism|May 13, 2017
<sup>LAPS</sup> Insulin115: A novel ultra-long-acting basal insulin with a unique action profileNina Wronkowitz, Thorsten Hartmann, Sven Wolfgang Görgens, et al.
Diabetes, Obesity & Metabolism|June 24, 2017
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individualsTania Garito, Ronenn Roubenoff, Marcus Hompesch, et al.
Diabetes, Obesity & Metabolism|December 8, 2020
Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trialsCarine Beysen, Patricia Schroeder, Eric Wu, et al.
Diabetes Care|June 9, 2016
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 DiabetesAndres Digenio, Richard L Dunbar, Veronica J Alexander, et al.
Plos One|December 18, 2018
Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patientsStanko Skrtic, Björn Tyrberg, Malin Broberg, et al.
Pageof 6